Lymphoma Clinical Trials in Hefei, Anhui
24 recruitingHefei, Anhui, China
Showing 1–20 of 24 trials
Recruiting
Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled195 locationsNCT06136559
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled246 locationsNCT06717347
Recruiting
Phase 1Phase 2
Evaluate the Safety and Clinical Activity of HH2853
Advanced Solid TumorPeripheral T Cell LymphomaFL Lymphoma+1 more
Haihe Biopharma Co., Ltd.254 enrolled25 locationsNCT04390737
Recruiting
Not Applicable
Anti CD19 Gene Therapy for B-cell Lymphoma
B-cell Lymphoma
Anhui Provincial Hospital18 enrolled1 locationNCT07211048
Recruiting
Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines150 enrolled64 locationsNCT06970743
Recruiting
Phase 2
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal (Jiangsu) Pharmaceutical Co., Ltd.66 enrolled15 locationsNCT07154264
Recruiting
Phase 2
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie110 enrolled31 locationsNCT02966756
Recruiting
Early Phase 1
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
Acute Lymphoblastic Leukemia (ALL), AdultNon-Hodgkin Lymphoma (NHL)
PersonGen BioTherapeutics (Suzhou) Co., Ltd.19 enrolled1 locationNCT07312630
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 2
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 2
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals155 enrolled17 locationsNCT06539182
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.68 enrolled29 locationsNCT07082686
Recruiting
Phase 3
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Peripheral T Cell Lymphoma
Dizal Pharmaceuticals218 enrolled50 locationsNCT07234162
Recruiting
Phase 1Phase 2
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Central Nervous System Lymphoma
Tong Chen, MD30 enrolled5 locationsNCT05698147
Recruiting
Phase 2Phase 3
Newly-diagnosed Pediatric T-cell ALL Protocol
Acute Lymphoblastic LeukemiaChildhood Leukemia, Acute LymphoblasticT Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China610 enrolled27 locationsNCT06855810
Recruiting
Phase 1
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Advanced Solid TumorAdvanced Lymphoma
CStone Pharmaceuticals480 enrolled38 locationsNCT05279300
Recruiting
Phase 2
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Multiple MyelomaLymphoma
Institute of Hematology & Blood Diseases Hospital, China120 enrolled7 locationsNCT05294055
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Early Phase 1
The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
B Lymphoblastic Leukemia/Lymphoma
Anhui Provincial Hospital9 enrolled2 locationsNCT06307600